Inclusion Criteria:  Newly-diagnosed NSCLC patients who will be undergoing concurrent chemotherapy and radiotherapy (XRT) followed by immune checkpoint inhibitors (CPI) therapy with durvalumab, as per the PACIFIC trial Willing to undergo all treatment and evaluation at MD Anderson Cancer Center (MDACC) Has access to a smartphone with the ability to transmit data via wireless connection or through their personal cellular plan Able and willing to perform home spirometry (HS) weekly without absolute contraindications to performing spirometry